糖鎖治療薬の世界市場レポート 2025年

糖鎖治療薬市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR17.4％で3,610億9,000万米ドルに成長します。予測期間の成長は、糖鎖生物学に関する知識の拡大、精密医療へのアプローチ、免疫療法への関心の高まり、希少疾患研究への資金提供の増加、糖鎖バイオマーカーの出現などに起因すると考えられます。予測期間の主な動向には、腫瘍学における糖鎖工学アプリケーションの拡大、治療用タンパク質の強化のための糖鎖工学、免疫腫瘍学における糖鎖工学の取り込み、希少疾患および遺伝性疾患における糖鎖工学、糖鎖医薬品の規制上の考慮事項などがあります。

糖尿病の有病率の上昇は、糖鎖治療薬市場の成長を促進すると予想されます。糖尿病は、血糖（グルコース）レベルを調節する身体の能力が損なわれる慢性疾患です。糖尿病患者では、糖鎖の変化が指摘されており、インスリン抵抗性やその他の代謝の問題につながる可能性があります。特定の糖鎖パターンは、糖尿病の診断、進行予測、治療反応のモニタリングのためのバイオマーカーとして機能します。例えば、2022年3月、ベルギーを拠点に糖尿病有病率に関する詳細なデータと洞察を提供する世界的リソースであるIDF Diabetes Atlasは、世界の糖尿病患者数が2030年の6億4,300万人から2045年には7億8,300万人に増加し、1億4,000万人増加すると予測しました。このように、糖尿病有病率の増加が糖鎖治療薬市場の拡大を牽引しています。

がん罹患率の上昇は、糖鎖治療薬市場の成長を促進します。制御不能な細胞増殖と拡散を特徴とするがんは、治療において糖鎖治療薬の応用が見られます。これらの治療薬は、細胞表面の特定の糖分子を標的として修飾し、重要な細胞間相互作用、シグナル伝達経路、免疫反応に影響を与え、腫瘍の成長を抑制し、がん治療の効果を高めることを目的としています。例えば、米国がん協会が報告したように、2023年に米国で新たに発生する女性の肝臓がんの推定症例数は、2022年の12,660例から13,230例に増加しました。したがって、がんの有病率の増加は、糖鎖治療薬市場の成長を促進する重要な要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界糖鎖治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の糖鎖治療薬市場：成長率分析
• 世界の糖鎖治療薬市場の実績：規模と成長, 2019-2024
• 世界の糖鎖治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界糖鎖治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の糖鎖治療薬市場：クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 孤立した
• 合成
• 世界の糖鎖治療薬市場構造別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 糖タンパク質
• シアル酸をターゲットに
• プロテオグリカン
• グリコサミノグリカンをターゲットにする
• グリコシルホスファチジルイノシトール（GPI）アンカータンパク質とヘパリンベースのグリカン
• スフィンゴ糖脂質を標的とする
• その他の構造
• 世界の糖鎖治療薬市場作用機序別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ノイラミニダーゼを阻害する
• ヘパラン分解酵素とセレクチンを阻害し、成長因子とヘパラン硫酸の相互作用を阻害します。
• エリスロポエチンと酵素補充療法（ERT）
• 組織プラスミノーゲン活性化因子
• グルコシルセラミド合成酵素を阻害する
• インターロイキン1、2、3
• ベータおよびガンマインターフェロン
• その他の作用機序
• 世界の糖鎖治療薬市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血栓症と化学予防
• 貧血
• 抗癒着性および抗炎症性
• 白内障
• ゴーシェ病
• MPS-1およびIV
• がん
• アルツハイマー病
• インフルエンザA型およびB型
• その他の適応症
• 世界の糖鎖治療薬市場、孤立したサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 天然グリカン
• グリカン誘導体
• 糖タンパク質
• 世界の糖鎖治療薬市場、合成のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学的に合成されたグリカン
• 組み換えグリカン
• 糖ペプチド

第7章 地域別・国別分析

• 世界の糖鎖治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の糖鎖治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 糖鎖治療薬市場：競合情勢
• 糖鎖治療薬市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck KGaA
• ICON plc
• Agilent Technologies Inc.
• AMS Bio
• Shimadzu Corporation
• Waters Corporation
• Bruker Corporation
• BioMarin Pharmaceutical Inc.
• Bio-Techne Corp.
• Promega Corporation
• Halozyme Therapeutics Inc.
• Takara Bio Inc.
• Vector Laboratories
• New England Biolabs Inc.
• Protalix Biotherapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 糖鎖治療薬市場2029：新たな機会を提供する国
• 糖鎖治療薬市場2029：新たな機会を提供するセグメント
• 糖鎖治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Glycomic therapeutics involves the application of glycomics-based approaches in the field of therapeutic development. The glycome, which constitutes the complete set of glycans in a cell or organism, plays a crucial role in understanding the intricate nature of biological systems and their implications for health and disease. Glycans are involved in diverse biological processes, including cell signaling, immune responses, and the development of diseases.

The primary types of glycomic therapeutics fall into two classes isolated and synthetic. Isolated glycomic therapy focuses on the study and analysis of glycans in isolation, delving into the structural and functional characterization of individual glycan molecules. Synthetic glycomic therapy involves the use of artificially created glycans or glycan-based molecules for diagnosing and treating various diseases or medical conditions. These therapies target different structures such as glycoproteins, sialic acid, proteoglycans, glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins, heparin-based glycans, glycosphingolipids, and others. The mode of action varies, including inhibiting neuraminidase, heparanase, selectins, blocking interactions between growth factors and heparan sulfate, and applications in erythropoietin and enzyme replacement therapy (ERT), tissue plasminogen activator, inhibiting glucosylceramide synthase, and targeting interleukins, interferons, among others. These therapies are employed for indications such as thrombosis and chemoprophylaxis, anemia, anti-adhesive and anti-inflammatory purposes, cataracts, Gaucher's disease, MPS-1 and IV, cancer, Alzheimer's disease, influenza types A and B, and more.

The glycomic therapeutics market research report is one of a series of new reports from The Business Research Company that provides glycomic therapeutics market statistics, including glycomic therapeutics industry global market size, regional shares, competitors with a glycomic therapeutics market share, detailed glycomic therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the glycomic therapeutics industry. This glycomic therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glycomic therapeutics market size has grown rapidly in recent years. It will grow from $164.71 billion in 2024 to $190.03 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to increased awareness of glycan significance, rise in chronic diseases, drug development for rare diseases, collaborations in glycomics research

The glycomic therapeutics market size is expected to see rapid growth in the next few years. It will grow to $361.09 billion in 2029 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to expanding knowledge of glycan biology, precision medicine approaches, rising interest in immunotherapy, increased funding for rare diseases research, emergence of glycan biomarkers. Major trends in the forecast period include expansion of glycomic applications in oncology, glycoengineering for enhanced therapeutic proteins, inclusion of glycomics in immuno-oncology, glycomics in rare and genetic disorders, regulatory considerations for glycomic drugs.

The rising prevalence of diabetes is anticipated to propel the growth of the glycomic therapeutics market. Diabetes is a chronic condition that impairs the body's ability to regulate blood sugar (glucose) levels. In individuals with diabetes, changes in glycans have been noted, which may lead to insulin resistance and other metabolic issues. Specific glycan patterns can act as biomarkers for diagnosing diabetes, forecasting its progression, and monitoring treatment responses. For example, in March 2022, the IDF Diabetes Atlas, a Belgium-based global resource that provides detailed data and insights on diabetes prevalence, projected that the global number of diabetes cases would rise from 643 million in 2030 to 783 million by 2045, representing an increase of 140 million cases. Thus, the growing prevalence of diabetes is driving the expansion of the glycomic therapeutics market.

The rising incidence of cancer is poised to drive the growth of the glycomic therapeutics market. Cancer, characterized by uncontrolled cell growth and spread, sees applications of glycomic therapeutics in treatment. These therapeutics target and modify specific sugar molecules on cell surfaces, influencing crucial cellular interactions, signaling pathways, and immune responses, with the goal of inhibiting tumor growth and enhancing the effectiveness of cancer therapies. For example, in 2023, the estimated number of new cases of liver cancer in females in the United States increased from 12,660 in 2022 to 13,230 in 2023, as reported by the American Cancer Society. Therefore, the increasing prevalence of cancer is a key factor driving the growth of the glycomic therapeutics market.

Product innovation stands out as a prominent trend gaining traction in the glycomic therapeutics market. Key players in the glycomic therapeutics sector are strategically investing in the development of cutting-edge technologies and innovative solutions to fortify their market position. For example, in April 2022, Glenmark Pharmaceuticals Limited, an Indian-based pharmaceutical company dedicated to discovering advanced therapies, introduced a novel fixed-dose combination (FDC) featuring a DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This innovative combination aims to enhance glycemic control and reduce insulin resistance in patients with type 2 diabetes.

Leading companies in the glycomic therapeutics sector are actively engaged in the creation of groundbreaking technological solutions, such as screening kits, to advance glycobiology research and exploration. A screening kit is a pre-packaged set of tools and materials designed for a preliminary test to detect the presence or absence of a specific substance, condition, or property. For instance, in July 2022, Vector Laboratories, a US-based provider of glycomic solutions, launched Glysite Scout Glycan screening kits. These kits, fully integrated for immunofluorescence, facilitate the detection of glycan expression in tissue sections, allowing researchers to profile and characterize complex glycans in biological systems and identify major surface glycan motifs in a sample.

In May 2022, Halozyme Therapeutics, a US-based biotechnology company, completed the acquisition of Antares Pharma Inc. for $960 million. This strategic move bolstered Halozyme's pipeline portfolio of novel treatments utilizing advanced drug delivery methods, enhancing safety, efficacy, convenience, tolerability, and patient comfort and adherence. Antares Pharma Inc. is a US-based pharmaceutical firm.

Major companies operating in the glycomic therapeutics market include F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, ICON plc, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd, Z Biotech LLC, Alzheon Inc., GlycoMar Limited

North America was the largest region in the glycomic therapeutics in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the glycomic therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glycomic therapeutics market consists of sales of investigational glycomic therapeutics and therapeutic glycomic that target glycans or glycan-related pathways for the diagnosis and treatment of diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glycomic Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glycomic therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glycomic therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glycomic therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Class: Isolated; Synthetic
• 2) By Structures: Glycoproteins; Targeting Sialic Acid; Proteoglycans; Targeting Glycosaminoglycans; Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans; Targeting Glycosphingolipids; Other Structures
• 3) By Mode Of Action: Inhibits Neuraminidase; Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate; Erythropoietin And Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 And 3; Beta And Gamma Interferons; Other Mode Of Action
• 4) By Indications: Thrombosis And Chemoprophylaxis; Anemia; Anti-Adhesive And Anti-Inflammatory; Cataracts; Gaucher's Disease; Mps-1 And IV; Cancer; Alzheimer's Disease; Influenza Type A And B; Other Indications
• Subsegments:
• 1) By Isolated: Natural Glycans; Glycan Derivatives; Glycoproteins
• 2) By Synthetic: Chemically Synthesized Glycans; Recombinant Glycans; Glycopeptides
• Companies Mentioned: F Hoffmann-La Roche Ltd.; Bayer AG; Sanofi SA; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Glycomic Therapeutics Market Characteristics

3. Glycomic Therapeutics Market Trends And Strategies

4. Glycomic Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Glycomic Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Glycomic Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Glycomic Therapeutics Market Growth Rate Analysis
• 5.4. Global Glycomic Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Glycomic Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Glycomic Therapeutics Total Addressable Market (TAM)

6. Glycomic Therapeutics Market Segmentation

• 6.1. Global Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Isolated
• Synthetic
• 6.2. Global Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glycoproteins
• Targeting Sialic Acid
• Proteoglycans
• Targeting Glycosaminoglycans
• Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin-Based Glycans
• Targeting Glycosphingolipids
• Other Structures
• 6.3. Global Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhibits Neuraminidase
• Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate
• Erythropoietin and Enzyme Replacement Therapy (ERT)
• Tissue Plasminogen Activator
• Inhibits Glucosylceramide Synthase
• Interleukin 1, 2, and 3
• Beta and Gamma Interferons
• Other Mode of Action
• 6.4. Global Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thrombosis and Chemoprophylaxis
• Anemia
• Anti-Adhesive and Anti-Inflammatory
• Cataracts
• Gaucher's Disease
• MPS-1 and IV
• Cancer
• Alzheimer's Disease
• Influenza Type A and B
• Other Indications
• 6.5. Global Glycomic Therapeutics Market, Sub-Segmentation Of Isolated, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natural Glycans
• Glycan Derivatives
• Glycoproteins
• 6.6. Global Glycomic Therapeutics Market, Sub-Segmentation Of Synthetic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemically Synthesized Glycans
• Recombinant Glycans
• Glycopeptides

7. Glycomic Therapeutics Market Regional And Country Analysis

• 7.1. Global Glycomic Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Glycomic Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glycomic Therapeutics Market

• 8.1. Asia-Pacific Glycomic Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glycomic Therapeutics Market

• 9.1. China Glycomic Therapeutics Market Overview
• 9.2. China Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glycomic Therapeutics Market

• 10.1. India Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glycomic Therapeutics Market

• 11.1. Japan Glycomic Therapeutics Market Overview
• 11.2. Japan Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glycomic Therapeutics Market

• 12.1. Australia Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glycomic Therapeutics Market

• 13.1. Indonesia Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glycomic Therapeutics Market

• 14.1. South Korea Glycomic Therapeutics Market Overview
• 14.2. South Korea Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glycomic Therapeutics Market

• 15.1. Western Europe Glycomic Therapeutics Market Overview
• 15.2. Western Europe Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glycomic Therapeutics Market

• 16.1. UK Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glycomic Therapeutics Market

• 17.1. Germany Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glycomic Therapeutics Market

• 18.1. France Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glycomic Therapeutics Market

• 19.1. Italy Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glycomic Therapeutics Market

• 20.1. Spain Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glycomic Therapeutics Market

• 21.1. Eastern Europe Glycomic Therapeutics Market Overview
• 21.2. Eastern Europe Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glycomic Therapeutics Market

• 22.1. Russia Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glycomic Therapeutics Market

• 23.1. North America Glycomic Therapeutics Market Overview
• 23.2. North America Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glycomic Therapeutics Market

• 24.1. USA Glycomic Therapeutics Market Overview
• 24.2. USA Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glycomic Therapeutics Market

• 25.1. Canada Glycomic Therapeutics Market Overview
• 25.2. Canada Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glycomic Therapeutics Market

• 26.1. South America Glycomic Therapeutics Market Overview
• 26.2. South America Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glycomic Therapeutics Market

• 27.1. Brazil Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glycomic Therapeutics Market

• 28.1. Middle East Glycomic Therapeutics Market Overview
• 28.2. Middle East Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glycomic Therapeutics Market

• 29.1. Africa Glycomic Therapeutics Market Overview
• 29.2. Africa Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Glycomic Therapeutics Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glycomic Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Glycomic Therapeutics Market Competitive Landscape
• 30.2. Glycomic Therapeutics Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Glycomic Therapeutics Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. ICON plc
• 31.3. Agilent Technologies Inc.
• 31.4. AMS Bio
• 31.5. Shimadzu Corporation
• 31.6. Waters Corporation
• 31.7. Bruker Corporation
• 31.8. BioMarin Pharmaceutical Inc.
• 31.9. Bio-Techne Corp.
• 31.10. Promega Corporation
• 31.11. Halozyme Therapeutics Inc.
• 31.12. Takara Bio Inc.
• 31.13. Vector Laboratories
• 31.14. New England Biolabs Inc.
• 31.15. Protalix Biotherapeutics Inc.

32. Global Glycomic Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glycomic Therapeutics Market

34. Recent Developments In The Glycomic Therapeutics Market

35. Glycomic Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Glycomic Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Glycomic Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Glycomic Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer